Biosign Launches Channel Partner Program

/THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

Biosign to deliver UFIT(R) monitors through leading software and hardware vendors

TORONTO , Nov. 23 /CNW/ - Biosign Technologies Inc. (CNSX: BIO) ("Biosign" or the "Company") announced today the formation of Biosign's Channel Partner Program ("CPP"). The program is open to companies commercializing products or services that integrate or extend Biosign health monitoring solutions. The goal is to enable growth, differentiation, and profitability through the provision of end-to-end solutions that seamlessly integrate monitoring and information technologies. Biosign will use the CPP to build a strong complement to the company's direct sales force to generate mutual sales and growth for Biosign and its sales partners by addressing imperative demands in health care markets.

Advances in information and communication technologies have created a large infrastructure for data transmission, storage and retrieval. Biosign's UFIT(R) platform effectively completes the "last mile" for these technologies by connecting non-invasively to objective data sources in the human body and generating quality assured information our partners' products can utilize meaningfully.

The health care market is changing rapidly. The demand for "more data" is being replaced with demands for "better data", shifting the emphasis from how data is recorded and shared to how data is gathered and analyzed. Accordingly, the initial focus is on partnerships with vendors of Personal Health Records, Electronic Medical Records, and Clinical Information Systems. Under the CPP, such vendors can integrate Biosign's health monitors toward satisfying the demand for simple, accurate and understandable statements of scientific fact about one's health.

Additionally, Biosign's CPP enables hardware manufacturers to turn their commercial-off-the-shelf products into advanced medical systems through the addition of UFIT(R) devices.

Biosign's CPP reflects the company's commitment to reward its partners through economic incentives, new ways to capitalize on Biosign innovations, preference with Biosign's sales organization, co-marketing opportunities, and a variety of service enablement programs. Partners that evolve and lead with Biosign have unprecedented opportunities to make a difference in health care.

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign please visit http://www.biosign.com.

The CNSX has neither approved nor disapproved the contents of this press release.

%SEDAR: 00014068E

For further information: Contact: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: [phone] ext. 234, Email: [email protected]